IL312261A - Novovirus vaccine and methods of use - Google Patents

Novovirus vaccine and methods of use

Info

Publication number
IL312261A
IL312261A IL312261A IL31226124A IL312261A IL 312261 A IL312261 A IL 312261A IL 312261 A IL312261 A IL 312261A IL 31226124 A IL31226124 A IL 31226124A IL 312261 A IL312261 A IL 312261A
Authority
IL
Israel
Prior art keywords
methods
norovirus vaccine
norovirus
vaccine
Prior art date
Application number
IL312261A
Other languages
English (en)
Hebrew (he)
Inventor
Elena Atochina-Vasserman
Drew Weissman
Original Assignee
Univ Pennsylvania
Atochina Vasserman Elena
Drew Weissman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Atochina Vasserman Elena, Drew Weissman filed Critical Univ Pennsylvania
Publication of IL312261A publication Critical patent/IL312261A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL312261A 2021-10-27 2022-10-27 Novovirus vaccine and methods of use IL312261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272439P 2021-10-27 2021-10-27
PCT/US2022/078753 WO2023076977A1 (en) 2021-10-27 2022-10-27 Norovirus vaccine and methods of use

Publications (1)

Publication Number Publication Date
IL312261A true IL312261A (en) 2024-06-01

Family

ID=86158598

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312261A IL312261A (en) 2021-10-27 2022-10-27 Novovirus vaccine and methods of use

Country Status (10)

Country Link
US (1) US20250018021A1 (https=)
EP (1) EP4422681A4 (https=)
JP (1) JP2024540061A (https=)
KR (1) KR20240111822A (https=)
CN (1) CN118450902A (https=)
AU (1) AU2022379626A1 (https=)
CA (1) CA3235832A1 (https=)
IL (1) IL312261A (https=)
MX (1) MX2024005194A (https=)
WO (1) WO2023076977A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4554617A1 (en) * 2022-07-13 2025-05-21 ModernaTX, Inc. Norovirus mrna vaccines
KR20260008117A (ko) * 2023-05-08 2026-01-15 머크 샤프 앤드 돔 엘엘씨 노로바이러스 vp1 항원을 코딩하는 폴리뉴클레오티드 및 그의 용도
KR20250123985A (ko) * 2024-02-08 2025-08-19 (주)한국바이오셀프 노로바이러스 GII mRNA를 포함하는 백신 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011276328C1 (en) * 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
US20160185826A1 (en) * 2014-08-07 2016-06-30 Medigen Biotechnology Corp. Virus-like particle vaccines
EP4631970A3 (en) * 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
WO2019104439A1 (en) * 2017-11-30 2019-06-06 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
US20250002539A1 (en) * 2021-07-26 2025-01-02 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus chimeric therapeutics

Also Published As

Publication number Publication date
JP2024540061A (ja) 2024-10-31
WO2023076977A1 (en) 2023-05-04
CN118450902A (zh) 2024-08-06
US20250018021A1 (en) 2025-01-16
AU2022379626A1 (en) 2024-05-30
EP4422681A1 (en) 2024-09-04
KR20240111822A (ko) 2024-07-17
CA3235832A1 (en) 2023-05-04
EP4422681A4 (en) 2025-11-19
MX2024005194A (es) 2024-07-22

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL312261A (en) Novovirus vaccine and methods of use
IL276687A (en) Trialkyne coupling agents and methods of using them
IL304680A (en) Urolithin history and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL292810A (en) Therapeutic compounds and methods of use
SG11202112978WA (en) Auto-injector and related methods of use
ZA202005674B (en) Glucoamylases and methods of use thereof
IL279633A (en) Immunoconjugates targeting ADAM9 and methods of using them
ZA202108213B (en) Klebsiella vaccine and methods of use
IL276053A (en) Therapeutic Gard and methods of its use
IL291180A (en) Bee vaccines and methods of use
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
WO2019070510A9 (en) Intrabody osteotomy implant and methods of use
GB2589398B (en) Compounds and methods of use
IL312041A (en) R-ketamine salts and methods of using them
IL286149A (en) Caspase inhibitors and methods of using them
IL284689A (en) Endoscopic device and methods of its use
GB2584782B (en) Entanglement device and method of use
EP3684406A4 (en) FILOVIRUS VACCINE AND METHODS OF USE
GB201811737D0 (en) Forceps and method of manufacture and use
HK40116097A (zh) 诺罗病毒疫苗及其使用方法
GB202119051D0 (en) Wingsail and method of use